Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03628287 · ClinicalTrials.gov registry record · NA
Program Refinements to Optimize Model Impact and Scalability Based on Evidence
A NA study, sponsored by City University of New York, School of Public Health.
- Completed
- Registry status
- NA
- Development phase
- 960
- Enrollment target
NCT03628287: Completed NA study, sponsored by City University of New York, School of Public Health.
NCT03628287 is a NA study that has completed, run by City University of New York, School of Public Health. The registered enrollment target is 960 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03628287, a NA study, has completed, sponsored by City University of New York, School of Public Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 960 participants
- Enrollment target
Study Summary
In New York, the achievement of 90-90-90 goals is jeopardized not by limited access to affordable care and treatment, but by persistent disparities in HIV viral suppression (VS). Complex behavioral and structural barriers to achieving and maintaining VS require coordinated, combination approaches to meet medical and social service needs. In 2009, at 28 Ryan White Part A (RWPA)-funded agencies, the New York City (NYC) Department of Health and Mental Hygiene (DOHMH) launched a multi-component HIV Care Coordination Program (CCP) directed toward the most vulnerable persons living with HIV (PLWH) in NYC. A systematic CCP effectiveness study began in 2013 (R01 MH101028; PIs: Irvine, Nash). Findings to date suggest that the CCP is superior to usual care for vulnerable subgroups of PLWH, but there remains substantial room for improvement in short- and long-term VS. In an immediate evidence-to-practice feedback loop, the DOHMH is implementing a refined CCP model in 2018. Greater focusing, tailoring and cues for delivery of key components are expected to increase CCP engagement, reach, fidelity, scalability, effectiveness and impact. The aim of the proposed study is to estimate the effect of the revised (vs. original) CCP on timely VS (within 4 months of enrollment), using experimental methods.
Primary Outcome
TVS defined as achieving viral suppression (VL \<200 copies/mL) on the last VL test in the four months following CCP enrollment.
Interventions
- OTHER Revised Care Coordination Program
- OTHER Original Care Coordination Program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 960 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2023-01-31 |
| Phase | NA |
What the finished NCT03628287 record still lists
NCT03628287 is an interventional study that assigns participants to a tested intervention. The registered 960 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 2 interventions - of which Revised Care Coordination Program is the first listed.
NCT03628287 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03628287 about?
NCT03628287 is a clinical study titled "Program Refinements to Optimize Model Impact and Scalability Based on Evidence". In New York, the achievement of 90-90-90 goals is jeopardized not by limited access to affordable care and treatment, but by persistent disparities in HIV viral suppression (VS). Complex behavioral and structural barriers to achieving and maintaining VS require coordinated, combination approaches to...
What is the current status of trial NCT03628287?
This trial is currently completed. It is a NA study. The enrollment target is 960 participants. The study started on 2018-08-01. Estimated completion is 2023-01-31.
What interventions are being tested in trial NCT03628287?
The interventions under investigation include: Revised Care Coordination Program (OTHER), Original Care Coordination Program (OTHER).
Who is sponsoring clinical trial NCT03628287?
This trial is sponsored by City University of New York, School of Public Health, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03628287's enrollment target sits among peer trials
960 123rd of 2000 higher than 1,878 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04726241 · 960 participants · Phase 1
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- NCT05142384 · 960 participants · NA
ICBT (Internet Based Cognitive Behavioral Therapy) for Maternal Depression: Community Implementation in Head Start
- NCT05178498 · 960 participants
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
- NCT05946629 · 960 participants · NA
SELUTION 4 De Novo Small Vessel IDE Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI